Overview

Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether exenatide is effective to improve glycemic control among type 2 diabetic patients treated by insulin pump therapy.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

University Hospital, Caen

Collaborator:

Eli Lilly and Company

Treatments:

Exenatide